Page last updated: 2024-08-17

diiodotyrosine and Colonic Neoplasms

diiodotyrosine has been researched along with Colonic Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Chen, C; Chen, G; Chen, X; Du, J; Gao, Y; Li, W; Ning, H; Pang, L; Qi, Y; Shen, W; Shi, R; Sui, X; Sun, Y; Wang, H; Wu, Y; Zhai, W; Zhao, W; Zhou, X	1

Other Studies

1 other study(ies) available for diiodotyrosine and Colonic Neoplasms

Article	Year
Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression. Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:11 Topics: Animals; Azoxymethane; B7-H1 Antigen; Biological Products; Colitis; Colonic Neoplasms; Diiodotyrosine; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Interleukin-15; Mice; Minor Histocompatibility Antigens; Mutation Accumulation; Programmed Cell Death 1 Receptor; Tumor Microenvironment	2022

Article

Year

Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression.

Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:11

Topics: Animals; Azoxymethane; B7-H1 Antigen; Biological Products; Colitis; Colonic Neoplasms; Diiodotyrosine; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Interleukin-15; Mice; Minor Histocompatibility Antigens; Mutation Accumulation; Programmed Cell Death 1 Receptor; Tumor Microenvironment

2022